SURVYR

SGRY

Surgery Partners, Inc.
$23.24
−$0.12 (0.51%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-50%-34%-18%-1%+15%Oct 2025Oct 2026Apr 202652w high $23.4452w low $11.41
SGRYSPY
Wall St. Highest PT $24.00 (+3.3%) Wall St. Avg PT $18.82 (-19.0%)
$11$15$18$21$25POC $15Hi $24Avg $19
Underwater Drawdown %Max DD -49.9%Current -0.5%
0.0%-49.9%
Relative Strength vs SPY-12.4% vs SPYUnderperforming
+65%0%-65%
1W
+$8.53 (57.99%)
1M
+$8.55 (58.20%)
3M
+$6.83 (41.62%)
6M
+$9.37 (67.56%)
YTD
+$7.79 (50.42%)
1Y
+$0.30 (1.31%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
12 analysts · mean score 2.17
1 = Strong Buy · 5 = Sell
Strong Buy18%
Buy867%
Hold325%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$23.24
Average target$18.82
−$4.42 (−19.0%) downsideaverage target vs current price
CurrentAverageMedian
Low$14.00
Median$19.00
High$24.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-09-30 · RBC Capital reiterated Outperform on SGRY
Reiterated
2026-09-18 · TD Cowen reiterated Buy on SGRY
Reiterated
2026-09-14 · JP Morgan reiterated Neutral on SGRY
Reiterated
2026-08-11 · TD Cowen reiterated Buy on SGRY
Reiterated
2026-08-11 · RBC Capital reiterated Outperform on SGRY
Reiterated
2026-08-11 · Cantor Fitzgerald reiterated Overweight on SGRY
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.1B
P/E (next 12 months, estimated)56.2
52-week range$11.41 – $23.44
Revenue growth (latest quarter vs a year ago)+2.7%
Dividend yieldNo dividend
Average analyst price target$18.82 (-19%)

What they do

Surgery Partners, Inc. owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.

Healthcare · Medical Care Facilities
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for SGRY yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

SGRY earningsNext report in 12 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Before the open
EPS consensus$0.12 range $0.10–$0.16
Revenue consensus$796.2M 4 analysts
Last 4 quarters · EPS vs estimate
Aug 10, 2026$0.10est $0.06+59.6%Above estimates
May 5, 2026-$0.03est -$0.14+77.8%Above estimates
Mar 2, 2026$0.12est $0.30−59.7%Below estimates
Nov 10, 2025$0.13est $0.16−19.0%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 01:17:46 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.140.44
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$848.9M+2.7%
2026-03-31$810.9M–
2025-12-31$885.0M–
2025-09-30$821.5M–
2025-06-30$826.2M–

News & catalysts

More news
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Surgery Partners, Inc. (NASDAQ: SGRY)
PR Newswire · 17h ago
Stock Market Today, Oct. 26: AI Optimism Lifts Nasdaq as Tech Stocks Rebound
Motley Fool · Oct 26
3 Profitable Stocks We’re Skeptical Of
StockStory · Oct 16
Rating changes
Reiterated
2026-09-30 · RBC Capital reiterated Outperform on SGRY
Reiterated
2026-09-18 · TD Cowen reiterated Buy on SGRY
Reiterated
2026-09-14 · JP Morgan reiterated Neutral on SGRY
Reiterated
2026-08-11 · TD Cowen reiterated Buy on SGRY
Reiterated
2026-08-11 · RBC Capital reiterated Outperform on SGRY
Reiterated
2026-08-11 · Cantor Fitzgerald reiterated Overweight on SGRY

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Deluca Teresa
Director · 2026-08-18
Buy
$143.5K

Stats refreshed 2026-10-26 01:17:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026